SCHEMBL8933520

SCHEMBL8933520

C=CCOc1ccc(-c2ccc(-c3ccc(C4CCC(/C=C/C)CC4)cc3F)cc2)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 10/20 0.35
HTR2B P41595 5/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
HTR2A P28223 6/20 0.32
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
APP P05067 2/20 0.31
FASN P49327 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
ADRB2 P07550 1/20 0.30
HTR1A P08908 1/20 0.30
CHRM5 P08912 1/20 0.30
ADRA2A P08913 1/20 0.30
DRD2 P14416 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8959373 0.97 HTR2C (0.33) HTR2CHTR2BPDE4APDE4BPDE4C
SCHEMBL8933399 0.91 HTR2C (0.35) HTR2CHTR2BPDE4APDE4BPDE4C
SCHEMBL8933414 0.90 KDM1A (0.39) PDE4ACYP3A4CYP2C9APPFASN
SCHEMBL12999623 0.88 CYP3A4 (0.31) HTR2CHTR2BPDE4APDE4BPDE4C
SCHEMBL8959304 0.88 HTR2C (0.34) HTR2CHTR2BPDE4APDE4BPDE4C
SCHEMBL8959330 0.87 KDM1A (0.37) CYP3A4CYP2C9APPFASNCYP2D6
SCHEMBL8933505 0.87 FPR2 (0.35) PDE4ACYP3A4CYP2C9APPFASN
SCHEMBL8933669 0.87 HTR2C (0.34) HTR2CHTR2BPDE4APDE4BPDE4C
SCHEMBL8933682 0.86 PDE4A (0.33) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL8944384 0.86 HTR2C (0.34) HTR2CHTR2BPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8187494-B2 Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-05-29 US disclosed
US-8187494-B2 Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-05-29 US disclosed
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE KIF23, HCN3, FZD7 HTR2C 447/4885HTR2B 1261/4885PDE4A 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.